Global Diabetic Retinopathy (DR) Analysis Software 麻豆原创 Research Report 2023

Publication ID:

PB511244425

Publication Date:

November 13, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

IT Services [2]

Computing & Electronics [3]

Description:

The software is artificial intelligence-based, composed of automated DR screening and mobile or hardware components. The goal is to bring long term and cheap diabetic retinopathy screening to diabetic patients through ML or mobile phones. The core technique for the analysis is deep learning module, and with the web interfaces, both doctors and patients could visually understand the results.
The global Diabetic Retinopathy (DR) Analysis Software market is projected to reach US$ 2045.2 million in 2029, increasing from US$ 1207 million in 2022, with the CAGR of 7.9% during the period of 2023 to 2029.
According to the Global Use of Medicines 2023 released by IQVIA Institute, the global drug expenditure in 2022 was about US$1.48 trillion (excluding COVID vaccine and treatment-related expenses), and it is predicted to grow at a rate of 3%-6% in the next few years. In terms of drug expenditure, this number in China was about 166 billion dollars in 2022. It is expected that the expenditure on medicines will increase in the next few years. From the perspective of demand, the trend of population aging, the increase of residents鈥� wealth and the improvement of health awareness will drive the demand for medicines.
Global Use of Medicines 2023 shows that the U.S. market spent about US$ 62.9 billion on medicines in 2022 on a net ex-factory basis. Overall growth slows as the Inflation Reduction Act (IRA) spends US$64 billion to reduce prescription drug prices, and the adoption of new treatments is expected to increase over the next few years. Besides, ex-factory discounts and rebates in drug distribution, the impact of patent expiration, and generic or biosimilar competition will also affect the U.S. pharmaceutical market.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Diabetic Retinopathy (DR) Analysis Software market with multiple angles, which provides sufficient supports to readers鈥� strategy and decision making.
By Company
Evolucare
IDx Technologies Inc.
Yingtong
Vistel
MONA
Eyenuk
Google Health
Optos
Zeiss
Heidelberg Engineering
Topcon Medical Systems
RetinAI
Remidio Innovative Solutions
Segment by Type
AI Screening System
AI Analysis (Disease Assessment)
Segment by Application
Clinical Diagnoses
Personal Triage
Investigational Use
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Diabetic Retinopathy (DR) Analysis Software report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. 麻豆原创 Opportunities and Challenges
Chapter 3: Companies鈥� Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies鈥� Outline
Chapter 12: 麻豆原创 Conclusions
Chapter 13: Research Methodology and Data Source

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Diabetic Retinopathy (DR) Analysis Software 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 AI Screening System
1.2.3 AI Analysis (Disease Assessment)
1.3 麻豆原创 by Application
1.3.1 Global Diabetic Retinopathy (DR) Analysis Software 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Clinical Diagnoses
1.3.3 Personal Triage
1.3.4 Investigational Use
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Diabetic Retinopathy (DR) Analysis Software 麻豆原创 Perspective (2018-2029)
2.2 Diabetic Retinopathy (DR) Analysis Software Growth Trends by Region
2.2.1 Global Diabetic Retinopathy (DR) Analysis Software 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 Diabetic Retinopathy (DR) Analysis Software Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 Diabetic Retinopathy (DR) Analysis Software Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 Diabetic Retinopathy (DR) Analysis Software 麻豆原创 Dynamics
2.3.1 Diabetic Retinopathy (DR) Analysis Software Industry Trends
2.3.2 Diabetic Retinopathy (DR) Analysis Software 麻豆原创 Drivers
2.3.3 Diabetic Retinopathy (DR) Analysis Software 麻豆原创 Challenges
2.3.4 Diabetic Retinopathy (DR) Analysis Software 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Diabetic Retinopathy (DR) Analysis Software Players by Revenue
3.1.1 Global Top Diabetic Retinopathy (DR) Analysis Software Players by Revenue (2018-2023)
3.1.2 Global Diabetic Retinopathy (DR) Analysis Software Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global Diabetic Retinopathy (DR) Analysis Software 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Diabetic Retinopathy (DR) Analysis Software Revenue
3.4 Global Diabetic Retinopathy (DR) Analysis Software 麻豆原创 Concentration Ratio
3.4.1 Global Diabetic Retinopathy (DR) Analysis Software 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Diabetic Retinopathy (DR) Analysis Software Revenue in 2022
3.5 Diabetic Retinopathy (DR) Analysis Software Key Players Head office and Area Served
3.6 Key Players Diabetic Retinopathy (DR) Analysis Software Product Solution and Service
3.7 Date of Enter into Diabetic Retinopathy (DR) Analysis Software 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Diabetic Retinopathy (DR) Analysis Software Breakdown Data by Type
4.1 Global Diabetic Retinopathy (DR) Analysis Software Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global Diabetic Retinopathy (DR) Analysis Software Forecasted 麻豆原创 Size by Type (2024-2029)
5 Diabetic Retinopathy (DR) Analysis Software Breakdown Data by Application
5.1 Global Diabetic Retinopathy (DR) Analysis Software Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global Diabetic Retinopathy (DR) Analysis Software Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America Diabetic Retinopathy (DR) Analysis Software 麻豆原创 Size (2018-2029)
6.2 North America Diabetic Retinopathy (DR) Analysis Software 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Diabetic Retinopathy (DR) Analysis Software 麻豆原创 Size by Country (2018-2023)
6.4 North America Diabetic Retinopathy (DR) Analysis Software 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Diabetic Retinopathy (DR) Analysis Software 麻豆原创 Size (2018-2029)
7.2 Europe Diabetic Retinopathy (DR) Analysis Software 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Diabetic Retinopathy (DR) Analysis Software 麻豆原创 Size by Country (2018-2023)
7.4 Europe Diabetic Retinopathy (DR) Analysis Software 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Diabetic Retinopathy (DR) Analysis Software 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific Diabetic Retinopathy (DR) Analysis Software 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Diabetic Retinopathy (DR) Analysis Software 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific Diabetic Retinopathy (DR) Analysis Software 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Diabetic Retinopathy (DR) Analysis Software 麻豆原创 Size (2018-2029)
9.2 Latin America Diabetic Retinopathy (DR) Analysis Software 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Diabetic Retinopathy (DR) Analysis Software 麻豆原创 Size by Country (2018-2023)
9.4 Latin America Diabetic Retinopathy (DR) Analysis Software 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Diabetic Retinopathy (DR) Analysis Software 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa Diabetic Retinopathy (DR) Analysis Software 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Diabetic Retinopathy (DR) Analysis Software 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa Diabetic Retinopathy (DR) Analysis Software 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Evolucare
11.1.1 Evolucare Company Detail
11.1.2 Evolucare Business Overview
11.1.3 Evolucare Diabetic Retinopathy (DR) Analysis Software Introduction
11.1.4 Evolucare Revenue in Diabetic Retinopathy (DR) Analysis Software Business (2018-2023)
11.1.5 Evolucare Recent Development
11.2 IDx Technologies Inc.
11.2.1 IDx Technologies Inc. Company Detail
11.2.2 IDx Technologies Inc. Business Overview
11.2.3 IDx Technologies Inc. Diabetic Retinopathy (DR) Analysis Software Introduction
11.2.4 IDx Technologies Inc. Revenue in Diabetic Retinopathy (DR) Analysis Software Business (2018-2023)
11.2.5 IDx Technologies Inc. Recent Development
11.3 Yingtong
11.3.1 Yingtong Company Detail
11.3.2 Yingtong Business Overview
11.3.3 Yingtong Diabetic Retinopathy (DR) Analysis Software Introduction
11.3.4 Yingtong Revenue in Diabetic Retinopathy (DR) Analysis Software Business (2018-2023)
11.3.5 Yingtong Recent Development
11.4 Vistel
11.4.1 Vistel Company Detail
11.4.2 Vistel Business Overview
11.4.3 Vistel Diabetic Retinopathy (DR) Analysis Software Introduction
11.4.4 Vistel Revenue in Diabetic Retinopathy (DR) Analysis Software Business (2018-2023)
11.4.5 Vistel Recent Development
11.5 MONA
11.5.1 MONA Company Detail
11.5.2 MONA Business Overview
11.5.3 MONA Diabetic Retinopathy (DR) Analysis Software Introduction
11.5.4 MONA Revenue in Diabetic Retinopathy (DR) Analysis Software Business (2018-2023)
11.5.5 MONA Recent Development
11.6 Eyenuk
11.6.1 Eyenuk Company Detail
11.6.2 Eyenuk Business Overview
11.6.3 Eyenuk Diabetic Retinopathy (DR) Analysis Software Introduction
11.6.4 Eyenuk Revenue in Diabetic Retinopathy (DR) Analysis Software Business (2018-2023)
11.6.5 Eyenuk Recent Development
11.7 Google Health
11.7.1 Google Health Company Detail
11.7.2 Google Health Business Overview
11.7.3 Google Health Diabetic Retinopathy (DR) Analysis Software Introduction
11.7.4 Google Health Revenue in Diabetic Retinopathy (DR) Analysis Software Business (2018-2023)
11.7.5 Google Health Recent Development
11.8 Optos
11.8.1 Optos Company Detail
11.8.2 Optos Business Overview
11.8.3 Optos Diabetic Retinopathy (DR) Analysis Software Introduction
11.8.4 Optos Revenue in Diabetic Retinopathy (DR) Analysis Software Business (2018-2023)
11.8.5 Optos Recent Development
11.9 Zeiss
11.9.1 Zeiss Company Detail
11.9.2 Zeiss Business Overview
11.9.3 Zeiss Diabetic Retinopathy (DR) Analysis Software Introduction
11.9.4 Zeiss Revenue in Diabetic Retinopathy (DR) Analysis Software Business (2018-2023)
11.9.5 Zeiss Recent Development
11.10 Heidelberg Engineering
11.10.1 Heidelberg Engineering Company Detail
11.10.2 Heidelberg Engineering Business Overview
11.10.3 Heidelberg Engineering Diabetic Retinopathy (DR) Analysis Software Introduction
11.10.4 Heidelberg Engineering Revenue in Diabetic Retinopathy (DR) Analysis Software Business (2018-2023)
11.10.5 Heidelberg Engineering Recent Development
11.11 Topcon Medical Systems
11.11.1 Topcon Medical Systems Company Detail
11.11.2 Topcon Medical Systems Business Overview
11.11.3 Topcon Medical Systems Diabetic Retinopathy (DR) Analysis Software Introduction
11.11.4 Topcon Medical Systems Revenue in Diabetic Retinopathy (DR) Analysis Software Business (2018-2023)
11.11.5 Topcon Medical Systems Recent Development
11.12 RetinAI
11.12.1 RetinAI Company Detail
11.12.2 RetinAI Business Overview
11.12.3 RetinAI Diabetic Retinopathy (DR) Analysis Software Introduction
11.12.4 RetinAI Revenue in Diabetic Retinopathy (DR) Analysis Software Business (2018-2023)
11.12.5 RetinAI Recent Development
11.13 Remidio Innovative Solutions
11.13.1 Remidio Innovative Solutions Company Detail
11.13.2 Remidio Innovative Solutions Business Overview
11.13.3 Remidio Innovative Solutions Diabetic Retinopathy (DR) Analysis Software Introduction
11.13.4 Remidio Innovative Solutions Revenue in Diabetic Retinopathy (DR) Analysis Software Business (2018-2023)
11.13.5 Remidio Innovative Solutions Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Evolucare
IDx Technologies Inc.
Yingtong
Vistel
MONA
Eyenuk
Google Health
Optos
Zeiss
Heidelberg Engineering
Topcon Medical Systems
RetinAI
Remidio Innovative Solutions

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.